This summer, an alliance of the world’s top plasma medicine companies expects to launch a clinical trial of a potential treatment for COVID-19. The unbranded “hyperimmune” aims to deliver a reliable dose of antibodies in a refined treatment that could be produced at scale and then stocked by hospitals. Learn more about how the process will work:
Donations of convalescent plasma are critical to the success of the effort. To learn more about donating, visit CoVIg-19PlasmaAlliance.org.
